PRPF31

Across TCGA pan-cancer cohorts, PRPF31 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PRPF31 data layer compared with 26 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PRPF31 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated PRPF31 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

HNSC, LUAD, and LSCC are the cancer types where PRPF31 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.561	0.892	.005	44	view →
LUAD	OS	Tertile	III,IV	0.795	0.495	.017	14	view →
LSCC	OS	Median	All	1.000	0.925	.014	11	view →
CCRCC	DFS	Quartile	II,III,IV	0.981	0.184	.036	4	view →
GBM	OS	Quartile	All	0.535	0.286	.028	4	view →
PDAC	DFS	Tertile	III,IV	0.253	0.572	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PRPF31–HNSC (OS)

Open the HNSC breakdown →